|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Herman, JD, Rice, DP, Ribacke, U, Silterra, J, Deik, AA, Moss, EL, Broadbent, KM, Neafsey, DE, Desai, MM, Clish, CB, Mazitschek, R, Wirth, DF|
|Keywords||Biological Evolution, Drug Resistance, Genomics, Humans, Malaria, Falciparum, Mutation, Piperidines, Plasmodium falciparum, Protozoan Proteins, Quinazolinones, Sequence Analysis, DNA|
BACKGROUND: Drug resistance remains a major public health challenge for malaria treatment and eradication. Individual loci associated with drug resistance to many antimalarials have been identified, but their epistasis with other resistance mechanisms has not yet been elucidated.
RESULTS: We previously described two mutations in the cytoplasmic prolyl-tRNA synthetase (cPRS) gene that confer resistance to halofuginone. We describe here the evolutionary trajectory of halofuginone resistance of two independent drug resistance selections in Plasmodium falciparum. Using this novel methodology, we discover an unexpected non-genetic drug resistance mechanism that P. falciparum utilizes before genetic modification of the cPRS. P. falciparum first upregulates its proline amino acid homeostasis in response to halofuginone pressure. We show that this non-genetic adaptation to halofuginone is not likely mediated by differential RNA expression and precedes mutation or amplification of the cPRS gene. By tracking the evolution of the two drug resistance selections with whole genome sequencing, we further demonstrate that the cPRS locus accounts for the majority of genetic adaptation to halofuginone in P. falciparum. We further validate that copy-number variations at the cPRS locus also contribute to halofuginone resistance.
CONCLUSIONS: We provide a three-step model for multi-locus evolution of halofuginone drug resistance in P. falciparum. Informed by genomic approaches, our results provide the first comprehensive view of the evolutionary trajectory malaria parasites take to achieve drug resistance. Our understanding of the multiple genetic and non-genetic mechanisms of drug resistance informs how we will design and pair future anti-malarials for clinical use.
|Alternate Journal||Genome Biol.|
|PubMed Central ID||PMC4272547|
|Grant List||AI084031 / AI / NIAID NIH HHS / United States |
GM104239 / GM / NIGMS NIH HHS / United States
T32 GM007306 / GM / NIGMS NIH HHS / United States
T32 GM007306-39 / GM / NIGMS NIH HHS / United States
R01 GM104239 / GM / NIGMS NIH HHS / United States
R21 AI084031 / AI / NIAID NIH HHS / United States